Kelly Guthrie, PA
Physician Assistant · West Chester, OHNPI 1093453862
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $559 and has fallen 71.6% since, to $159 in 2025.
Across 19 payments — averaging $49.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$218
- E.r. Squibb & Sons, L.L.C.$159
- Johnson & Johnson$125
- Daiichi Sankyo Inc.$117
- Stemline Therapeutics Inc.$92
- Seagen Inc.$85
- plus $149 from 6 others
What the payments were for
- Food & beverage$87793%
- Education$677%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 3 | $218 |
| E.r. Squibb & Sons, L.L.C. | 4 | $159 |
| Johnson & Johnson | 1 | $125 |
| Daiichi Sankyo Inc. | 1 | $117 |
| Stemline Therapeutics Inc. | 1 | $92 |
| Seagen Inc. | 2 | $85 |
| Tersera Therapeutics LLC | 2 | $44 |
| AbbVie | 1 | $29 |
| Merck | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$944 in reported general payments places this provider in the 75th percentile of 4,098 physician assistant providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $12,379 |
| Exemestane | 11 | $4,261 |
| Letrozole | 57 | $937 |
| Anastrozole | 24 | $417 |
| Oxycodone Hcl | 20 | $407 |
| Dexamethasone | 17 | $276 |
| Prochlorperazine Maleate | 15 | $224 |
| Prednisone | 16 | $84 |
Paid to pharmacies, not to this prescriber.
Other physician assistant in West Chester
- Steven WurzelbacherCincinnati$309K
- Emily AnkromDayton$192K
- Amanda MaggartWorthington$164K
- Megan SevillaMayfield Heights$132K
- Erin StrculaBelpre$106K
- Sarah LaubNew Albany$100K
- Jessica RhominskiCanal Winchester$78K
- Brook GramBeloit$52K
- Alison FleigToledo$48K
- Alicia PerkinsColumbus$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.